FDA & Product Rules

FDA Tobacco Chief Says Flavored Vapes Do Not Need Built-In Age Locks to Win Authorization

CTP Director Bret Koplow told Glas in an October 26, 2026 letter that FDA does not require device access restrictions for flavored ENDS to be authorized. The letter followed Glas's complaint about flavored Vuse Pro pods sold for use with the Vuse Alto.

E-commerce 4 Internet Marketers Editorial
Card Network Programs

Mastercard’s New Merchant Audit Program Counts Fraud Reports and Chargebacks Together From April 2027

Mastercard replaces its Acquirer Chargeback Monitoring Program with the Global Merchant Audit Program on April 1, 2027. New HDM and EDM categories count fraud reports plus non-fraud chargebacks, and the ECM band tightens from 2029.

E-commerce 4 Internet Marketers Editorial
Regulatory & Compliance

Google Ads Will Accept NABP Accreditation for Telemedicine Certification

Google said on November 4, 2026 that telemedicine advertisers accredited through NABP's Healthcare Merchant Accreditation Program will be able to apply for Google Ads certification in the US, Canada and the UK once a November policy update is published. As of November 13 the live policy still names only LegitScript.

E-commerce 4 Internet Marketers Editorial
Regulatory & Compliance

Amazon Now Requires $1 Million Liability Cover From Supplement Sellers of Any Size

Since November 2, 2026, third-party sellers with supplements and other products in Amazon's enhanced safety categories must carry $1 million in commercial liability insurance whatever their monthly sales, and Mainland China sellers must buy new policies through the Amazon Insurance Accelerator.

E-commerce 4 Internet Marketers Editorial
FDA & Product Rules

FDA Warns RonanRx Over American-Made Claims for Compounded GLP-1s

FDA's October 30, 2026 warning letter to RonanRx says a video calling its compounded semaglutide and tirzepatide "American made" and "farm-to-table drugs" was misleading because FDA lists no U.S. maker of the active ingredients. It also cites implied FDA approval and RonanRx-branded labels.

E-commerce 4 Internet Marketers Editorial
FDA & Product Rules

HHS Lets Pharmacies Compound BPC-157 and Five Other Peptides but Leaves Research-Use Sellers Out

HHS's October 28, 2026 interim enforcement discretion policy lets 503A pharmacies and physicians compound BPC-157, TB-500, Epitalon, KPV, MOTS-c and Semax under ten conditions, without adding them to the bulks list. Research-use-only sellers are left out, and comments close November 13.

E-commerce 4 Internet Marketers Editorial